Royalty Report: Drugs, Personal Care Products, Therapeutic – Collection: 27978

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 7

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 7

Primary Industries

  • Drugs
  • Personal Care Products
  • Therapeutic
  • Pharmaceuticals
  • Supply
  • Delivery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 27978

License Grant
The University grants to Licensee a world-wide license under  the University's Patent Rights to make, have made, use, sell, offer to sell and import Licensed Product and to practice Licensed Method to the extent permitted by law.  The University also grants to Licensee the right to issue sublicenses to third parties to make, have made, use, sell, offer to sell and import Licensed Product and to practice Licensed Method in the Field of Use as long as Licensee has current exclusive rights thereto under this Agreement.
License Property
Certain inventions, generally characterized as “Lipids for Epidermal Moisturization and Repair of Barrier Function”.

The Licensor for barrier repair technology is a technology that is a specific combination of ceramides, cholesterol and fatty acids which are able to create a human-like skin barrier and thus provide patients with a more normal skin barrier function.

The Barrier Repair platform represents near term revenue opportunities for prescription skin care products to treat a variety of skin disorders all characterized by a disrupted skin barrier.  In April 2006, the licensor received clearance from the United States Food and Drug Administration (FDA) to market EpiCeram® their first commercial product using the Barrier Repair technology.  EpiCeram® is a prescription-only topical cream intended to treat dry skin conditions and to manage and relieve the burning and itching associated with various types of dermatoses including atopic dermatitis (eczema), irritant contact dermatitis, and radiation dermatitis.

Field of Use
Field of Use means therapeutic and cosmetic applications in mammals, including humans.

IPSCIO Record ID: 6219

License Grant
Licensor hereby grants to Licensee worldwide sublicense under the Licensed Patents to make, have made, use, import, offer to sell, sell and have sold Licensed Products and the Licensed Method in the Licensed Field.

The Licensee has the right to use the Barrier Repair technology (skin care products to treat a variety of skin disorders all characterized by a disrupted skin barrier) to develop and market cosmetic, non-prescription products.

License Property
“Barrier Repair Technology” means the specific combination of ceramides, cholesterol and fatty acids which are able to create a human-like skin barrier embodied in the Licensed Patent.

“Licensed Patent” means U.S. Patent No. 5,643,899, all reissues.

“Triceram™” means a ceramide dominated formulation of the Licensed Product.

Field of Use
“Licensed Field” means cosmetic, non-prescription uses of the Barrier Repair Technology.

IPSCIO Record ID: 2271

License Grant
In 1989, the Company discontinued its operations and assigned its the rights to Skin Fresh Methodology.
License Property
Skin Fresh Methodology  for the treatment of acne, eczema, psoriasis, contact dermatitis, seborrhea, and other less serious skin disorders.

The Skin Fresh treatment program avoids the use of prescription drugs taken internally, and includes a regimen and the topical application of FDA approved antibiotics.

IPSCIO Record ID: 29106

License Grant
Pursuant to the Agreement, the Licensee acquired an exclusive North American license to certain patent rights and other intellectual property relating to a topical skin lotion product candidate using sodium cromoglicate for the treatment of atopic dermatitis (Altoderm). The Licensee may sublicense the patent rights.
License Property
Altoderm is  a proprietary formulation of topical cromolyn sodium for the treatment of atopic dermatitis.
Field of Use
Atopic dermatitis (AD) (a type of eczema) is an inflammatory, chronically relapsing, non-contagious and pruritic skin disease.

IPSCIO Record ID: 1884

License Grant
The Company entered into a Metabolic Moisturizer OTC License Agreement and the Azelaic Acid Agreement dated April 16, 1992 which granted to an exclusive, worldwide royalty-bearing license relates to the Company’s barrier repair technology.
License Property
Glylorin is a consumer products based on another premise underlying its core technology, that repairing the skin barrier may improve the skin’s ability to protect against environmental and occupational insults and thus may help prevent skin diseases and help alleviate conditions such as photoaging and wrinkling.

IPSCIO Record ID: 1724

License Grant
The Company entered into a second exclusive, worldwide, royalty bearing license agreement with the University for two patents, the rights to which are jointly held by the Licensor and Cellegy, for Drug Delivery By Skin Barrier Disruption.
License Property
This technology selectively modulates the skin’s barrier, with the goals of opening the skin barrier wider and keeping it open for a longer period of time (which may allow for the transdermal and topical delivery of larger and/or water soluble therapeutic, nutritional and cosmetic molecules), and reducing the potential for inducing skin inflammation, which sometimes accompanies use of certain traditional drug delivery technologies.
Field of Use
The rights granted apply to skin's barrier.

IPSCIO Record ID: 2279

License Grant
The Company is granted this exclusive Sub-License for use of the Technology for the Licensed Uses within the Territory for a period of eighteen months from the date of the execution of this Sub-License Agreement.
License Property
The technology refers certain proprietary information, technology and patents including solutions, ointments, creams and lotions, and particular ingredients utilized to develop such products.  The particular proprietary information, technology and patents (hereinafter the Technology) are more fully detailed in Patents numbered 5,015,474 and 5,248,501.
Field of Use
The rights granted apply for use as topical epidermal skin care products, including products for lips and skin.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.